title: New H1/H3 antagonists for treating allergic rhinitis: WO2010094643.
abstract: This application claims dual receptor specificity antihistamines, active as H(1) and H(3) antagonists, which additionally have a long duration of action that renders them suitable for once daily administration via inhalation for the treatment of allergic rhinitis. The compounds lack CNS penetration and have a high affinity for both histamine receptors.
authors.affiliation: Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. petrosn@bigfoot.com
authors.forename: Peter
authors.initials: P
authors.lastname: Norman
mesh_terms: D000818:Animals; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D054828:Histamine H3 Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use*; D010330:Patents as Topic; D010793:Phthalazines / Q000494:pharmacology / Q000627:therapeutic use*; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D013329:Structure-Activity Relationship
chemical_list: C558853:GSK 1004723; C558852:GSK 835726; D006634:Histamine H1 Antagonists; D054828:Histamine H3 Antagonists; D009281:Naphthalenes; D010793:Phthalazines; D010880:Piperidines